INTRODUCTION
Hepatic fi brosis is the end result of chronic liver diseases induced by a variety of stimuli including persistent infection, toxins, viruses, bacteria, parasites and autoimmune reactions [1, 2] . Hepatic fi brosis is defi ned as the excessive accumulation of extracellular matrix (ECM) proteins including collagen. As fi brotic liver diseases advance, progression from collagen bands to bridging fi brosis to frank cirrhosis occurs. Accordingly, cirrhosis can be defi ned as an advanced stage of fi brosis involving the formation of regenerative nodules of parenchyma surrounded and separated by fi brotic septa, a scenario also characterised by signifi cant changes in hepatic angioarchitecture. Generally, the mechanism for the origin and development of liver fi brosis and cirrhosis is not fully known, and from the stand point of today's knowledge it includes: persistence of parenchymal damage with variable degree of necrosis and apoptosis; presence of a heterogeneous infl ammatory infi ltrate including mononuclear cells and cells of the immune system; activation of different types of ECM-producing and myofi broblast-like cells with marked proliferative, synthetic and contractile features; and qualitative and quantitative changes of hepatic ECM, associated with limited or absent remodeling in the presence of a persistent attempt of hepatic regeneration. Many studies have clearly demonstrated that hepatic fi brosis is reversible in experimental rodent models (alcohol feeding, CCl4, or bile duct ligation). Upon removal of the etiological source of the chronic injury, regression of liver fi brosis is associated with decreased cytokines and ECM production, increased collagenase activity, disappearance of myofi broblasts (MFs) population and dissolution of the fi brous scar. Only recently has the fate of these MFs been revealed. The previous concept was that the MFs undergo apoptosis on the basis of documented senescence during reversal of fi brosis. Some authors have used genetic marking to demonstrate an alternative pathway in which MFs revert to a quiescent-like phenotype in CCl4-induced liver injury. Genetic marking of MFs enabled the quantitative mapping of the fate of these cells in experimental models of fi brosis and its reversal [3, 4] .
In the progression of chronic liver entry to fi brosis, all hepatic cells undergo specifi c changes. The hepatocytes are injured and they undergo apoptosis. The sinusoidal endothelial cells undergo a loss of fanestrae that is termed acapillarization of the sinusoids. The resident macrophages in the liver, the Kupffer cells, activate and produce a variety of chemokines and cytokines. Lymphocytes infi ltrate the injured liver and contribute to the infl ammation. Finally, the quiescent stellate cells are activated to produce extracellular matrix proteins. Development of liver fi brosis entails major alterations in both quantity and quality of hepatic ECM. In advanced stages, the liver contains approximately 6 times more ECM than normal, including collagens (I, III, and IV), fi bronectin, undulin, elastin, laminin, hyaluronan, and proteoglycans. Accumulation of ECM results from both increased synthesis and decreased degradation. Decreased activity of ECM-removing matrix metalloproteinases MMPs is mainly due to an overexpression of their specifi c inhibitors -tissue inhibitor of matrix metalloproteinases. Hepatic stellate cells (HSCs) are the main ECM-producing cells in the injured liver. There is overwhelming evidence that activated MFs are the major source of the components of ECM [5] . The cells responsible for fi brosis in all chronic liver diseases appear to be the activated MFs.
MFs are the main effectors of fi brosis in all tissues. They also make a major contribution to other aspects of the wound healing response, including regeneration, infl ammation, and angiogenesis, normal tissue repair after acute injury and to the stromal reaction in tumors [6] . They combine phenotypic features of fi broblasts, such as the production of ECM, with the contractile functions of smooth muscle cells involved in tissue architecture distortion. During progression of chronic liver fi brosis, resident hepatic cells undergo specifi c changes and begin to produce extracellular matrix proteins. In normal conditions, fi broblastic cells exhibit few or no actin-associated cell-cell and cellmatrix contacts and little ECM production. After tissue injury, they become activated to migrate into the damaged tissue and to synthesize ECM components by cytokines locally released from infl ammatory and resident cells [7] [8] [9] .
GENERAL CHARACTERISTICS OF MFS
The role of MFs in different pathological processes is well established. Recent reports of several studies performed on human patients indicate that myofi broblasts have an important role in the synthesis of ECM components and development liver fi brosis and cirrhosis. Studies of primary cultures of MFs and in mouse models of hepatic fi brosis have revealed several common pathophysiological mechanisms such as oxidative stress, increased transforming growth factor beta, hepatocyte death and chronic infl ammation.
Liver fi brogenesis is sustained by populations of highly proliferative, pro-fi brogenic and contractile MFs that, according to current literature, originate by a process of activation involving perisinusoidal HSC, portal fi broblasts and even bone marrow-derived MFs. According to the morphological and functional characteristics of MFs, these cells are between fi broblasts and smooth-muscle cells. MFs are capable of expressing a variety of cytoskeletal proteins which are used as markers of their differentiation. MFs contain microfi lament bundles and/or stress fi bers in the cytoplasm which play an important role in the mechanism of contraction that is similar to the mechanism of contraction of smooth-muscle cells [10] [11] [12] .
Three different MFs-like cells have been described in rats and humans based on the location and immunohistochemical profi le. These comprise: a) portal or septal MFs, present in the portal areas, or in newly formed fi brous septa, and for the most part come from the portal fi broblasts, b) interface MFs, present at the interface between parenchyma and stroma of the portal areas or newly formed fi brous septa and according to their antigen profi le, probably originate from activated hepatic stellate cells, and c) the perisinusoidally located HSCs originating from quiet inactive HSCs [13] [14] [15] [16] [17] .
ORIGIN OF MFS
During liver development, the septum transversum-derived mesothelium, which signals to induction of hepatogenesis from the foregut endoderm, gives rise to sinusoidal pericytes, called hepatic stellate cells (HSCs), and perivascular mesenchymal cells, including portal fi broblasts, smooth muscle cells and fi broblasts around the central veins. All these cells therefore have a common mesodermal origin, different from that of sinusoidal endothelial cells, Kupffer cells and hepatoblasts. It is now more than 35 years since the initial demonstration by Hans Popper and coworkers that transitional cells with the morphologic characteristics of vitamin A-containing cells (i.e. HSCs) and fi broblasts overproduce fi brillar collagen in rats with carbon tetrachloride-induced liver injury. The paradigm of HSCs activation giving rise to MFs has since dominated the focus of research on liver fi brosis. HSC was the fi rst major cell type in the liver to be identifi ed as a prominent source of collagen production in the injured liver [6, 17] .
Currently, the origin of the acitvated MFs is unresolved, and several cells potentially can fulfi ll this role. The MFs may be derived from a variety of sources including resident mesenchymal cells, epithelial to mesenchymal transition, as well as from circulating fi broblast-like cells called fi brocytes that are derived from bone-marrow stem cells, or derived from bone marrow precursors [2, 7, 18] . Also, MFs derived from small portal vessels proliferate around biliary tracts in cholestasis-induced liver fi brosis to initiate collagen deposition [19] [20] [21] . The bone marrow-derived fi brocytes, or circulating mesenchymal cells, can migrate through the injured liver and become MFs to participate in the fi brotic process. These circulating mesenchymal stem cell progenitors have a fi broblast/myofi broblast-like phenotype and they express CD34, CD45 and type I collagen [2, 22] . Alternatively, there is a limited amount of evidence that hepatocytes, cholangiocytes, or even endothelial cells may undergo a transition to mesenhymal cells to become activated MFs. For hepatocytes and cholangiocytes, this process is called the epithelial-to-mesenhymal transition or EMT. Finally, the resident cells in the liver may be activated to become MFs [23] .
Portal fi broblasts found in the connective tissue around blood vessels and bile ducts, are the dominant source of MFs (mainly portal and septal) in the development of fi brosis induced by bile duct ligation. Portal fi broblasts are a heterogeneous population and represent one of several fi broblast populations in the liver. The term "portal fi broblast" refers to any fi broblast in the portal region, and the term "portal MFs" to any MFs that originates in the portal area and is not derived from HSCs. In addition to portal fi broblasts, in chronic viral hepatitis fi brogenic cells located on the interface between the portal and parenchymal area are the main precursors of MFs. The second layer fi broblasts located around the central veins are the most important source of MFs in the development of alcoholic liver fi brosis and cirrhosis [4, 8, 10, 13, 16, 24, 25] .
Each of the mentioned sources of activated MFs participate with varying percentage in the synthesis of the ECM depending on the organ in which fi brosis is developed. HSCs have the most important role in ECM synthesis during the development of fi brosis in liver. These cells contribute 70-80% of all matrix-producing cells in the liver. The contribution of MFs in the ECM component synthesis depends on their origin. It was proven that MFs derived from the local fi broblasts constitute 4-6% of all collagen-producing cells, and MFs derived from bone marrow fi broblasts / fi brocytes are 8-12% of all collagen-producing cells. The percentage contribution of MFs created by the EMT is not known [10, 26] .
Moreover, immunohistochemical studies have shown that, in fi brotic human or rat liver, portal and septal myofi broblasts have expression profi les different from those of interface myofi broblasts or perisinusoidally located HSCs, suggesting that at least two subpopulations of myofi broblasts -HSC-derived myofi broblasts (HSC-MFs) and portal mesenchymal cell-derived myofi broblasts (PMFs) -populate the injured liver [6] .
Activation of portal fi broblasts, and their transformation in MFs, is usually caused by ischemic conditions and biliary obstructive cholestatic diseases. Due to the very similar antigen-expressing features it is believed that the portal and septal MFs have an identical origin [16, 21, 27, 28] .
Some studies have confi rmed that in the chronic liver damage profi brogenic MFs (mainly interface MFs and portal MFs) are derived from bone marrow mesenchymal stem cells and circulating fi broblasts [25, 28] . In carbon tetrachloride induced fi brosis, 33% of liver MFs expresses markers (CD11b, MHCII i F4/80) which are typical for bone marrow derived cells [10, 25, 26] .
Epithelial-to-mesencymal transition (EMT) is the process of transdifferentiation of differentiated epithelial cells followed by phenotypic changes and transition into differentiated mesenchymal cells -fi broblasts and MFs. Basically, this process means reprogramming of gene expression, modifi cation of transcription processes, architecture, adhesion and the ability to migrate. Several steps are critical for EMT: 1) disruption of local basement membrane; 2) loss of epithelial cell adhesion; 3) reprogramming of signaling machinery and de novo synthesis of α-smooth muscle actin (α-SMA); and 4) rearrangement of cytoskeletal proteins and transmigration of epithelial cells through the basement membrane into the interstitial space [26, 29, 30] .
Biliary epithel cells expression of S100A4, an early fi broblast lineage marker established as a robust marker of EMT, as well as vimentin, α-SMA and pSmad 2/3 were identifi ed in liver tissue from patients with primary biliary cirrhosis. This result suggests that EMT of biliary epithelial cells is occurring and that this process is driven by TGF-β [31] .
HSCS AS A MAJOR SOURCE OF MFS
HSCs are a heterogeneous group of cells that are functionally and anatomically similar, but they differ in the expression of cytoskeletal fi laments, the retinoid contents and the potential for the formation of ECM. HSCs pathologists have known for more than a century, ever since the moment when they were in 1876 described by von Kupfer. HSCs have been described in several mammalian species, including humans, but also in lower vertebrates, such as fi sh. Several decades ago, the role of the HSC in the deposition of lipo-soluble vitamin A in its stable form was described. These cells were previously called Ito cells, lipocytes or perisinusoidal cells. HSCs reside in the space of Disse and in normal conditions have the function in vitamine A storage in the form of retinyl esters. Following chronic liver injury, HSCs proliferate, lose their vitamin A and undergo a major phenotypical transformation to α-SMA positive MFs which produce a wide variety of collagenous and non-collagenous ECM components [32] [33] [34] [35] . HSCs are the primary source of ECM in the normal and fi brotic liver. Today there is substantial evidence that HSCs are the most important source for the production of collagen and noncollagenous ECM proteins. The discovery of the role of HSCs in the development of liver fi brosis is directed towards testing the evidence of their importance for prognosis and possible treatment of liver fi brosis [36] [37] [38] [39] .
The nature of HSCs, which are traditionally grouped into cells of mesenchymal origin because of their morphological appearance, as well as expression of molecules such as vimentin, desmin and α-SMA, is brought under question, because numerous studies clearly demonstrate the expression of neural and neuroendocrine markers, such as the glial fi brilar acid protein (GFAP), nestin, synaptophysin and neurotrophin receptor suggesting that HSCs originate from the neural crest [13, 40] . Some authors assume the possible epithelial origin of these cells and the potential EMT that occurs during their activation [36] .
In normal human liver HSCs accounted for about 1.4% of the total volume of the liver, and 15% (according to some authors 5-8%) of the total number of cells located in the liver. The number of HSCs is 3.6 to 6 HSCs per 100 hepatocytes or in a ratio of 1 HSC to 20 hepatocytes [10, 41] . HSCs have a stellar appearance due to their dendritic cytoplasmic extensions that are partly linked to neighboring endothelial cells and extending between hepatocytes and communicate with other cytoplasmic extensions of HSCs [36, 40, 41] . HSCs consist of a body and a number of dendritic extensions. The increase in contractility, loss of normal storage capacity for retinoids, increasing the amount of granular endoplasmic reticulum, changes in the organization of the cytoskeleton and cell morphology as well as acquiring the ability to synthesize ECM are the most important phenotypic characteristics of activated HSCs. Loss of fat droplets is considered to be the earliest morphological change indicating the activation of HSCs. Loss of fat droplets takes place after HSCs activation of hydrolysis of retinyl esters needed in order for retinol to leave the cell. HSCs showing properties of peaceful and activated cells are often referred to as transitional cell [19, 37, [40] [41] [42] [43] .
ACTIVATION OF MFS
After hepatic injury, MFs activation and migration to damaged tissue, as well as synthesis of ECM components take place. Cytokines that are locally released from infl ammatory and resident cells of the liver have a key role in the activation process as well as in MFs phenotype changes. In addition to cytokines, an essential role in the phenotypic change has the microenvironment in which the MFs are.
It is helpful to understand the pathophysiology of hepatic fi brosis based on the framework of hepatic stellate cell activation. Activation consists of two major phases, initiation (also called a "preinfl ammatory stage") and perpetuation, followed by a resolution phase when liver injury resolves. Initiation refers to early changes in gene expression and phenotype that render the cells responsive to other cytokines and stimuli. Initiation results mostly from paracrine stimulation, primarily due to changes in the surrounding extracellular matrix, as well as exposure to lipid peroxides and products of damaged hepatocytes [19, [43] [44] [45] . Perpetuation results from the effects of these stimuli on maintaining the activated phenotype and generating fi brosis. Perpetuation involves autocrine as well as paracrine loops. It is comprised of several discrete responses including proliferation, contractility, fi brogenesis, matrix degradation, retinoid loss, and infl ammatory cell infi ltration [40, 42] . Resolution of fi brosis refers to pathways that either drive the stellate cells to apoptosis, or contribute to their reversion to a more quiescent phenotype.
MFs are activated by a variety of mechanisms, including paracrine signals derived from lymphocytes and macrophages, autocrine factors secreted by MFs, and pathogenassociated molecular patterns (PAMPS) produced by pathogenic organisms that interact with pattern recognition receptors (i.e. TLRs) on fi broblasts. The interaction between PAMPs and PRRs serves as a fi rst line of defence during infection and activates numerous proinfl ammatory cytokine and chemokine responses. Thus, inhibiting TLR signalling might represent a novel approach to treat fi brotic disease. Cytokines (IL-13, IL-21, TGF-β1), chemokines (MCP-1, MIP-1β), angiogenic factors (VEGF), growth factors (PDGF), peroxisome proliferator-activated receptors (PPARs), acute phase proteins (SAP), caspases, and components of the renin-angiotensin-aldosterone system (ANG II) have been identifi ed as important regulators of fi brosis and are being investigated as potential targets of antifi brotic drugs [2] .
Although each of the mentioned cells releases mediators which have different effects on cells in the production of ECM components, undoubtedly the greatest number of papers highlights the role of PDGF and TGF-β. PDGF, mainly produced by Kupffer cells, is the predominant mitogen for activated HSCs that stimulates their proliferation, while TGF-β is considered the most important cytokine that stimulates HSCs to fi brogenesis [19, 44, 46] .
Various cytokines and growth factors have a role in the process of MFs activation. Among these, soluble factors stimulate fi brogenic cell activation, especially transforming growth factor-β1 (TGF-β1), a potent inducer of myofi broblastic differentiation. Beyond a specifi c effect on the induction of α-smooth muscle expression, TGF-β1 also promotes the deposition of large amounts of extracellular matrix [47] .
After tissue injury, fi broblasts differentiate into contractile and secretory myofi broblasts that contribute to tissue repair during wound healing, but that can severely impair organ function when contraction and ECM protein secretion becomes excessive. At least three local events are needed to generate α-SMA-positive differentiated myofi broblasts: 1) accumulation of biologically active TGF-β1, 2) the presence of specialized ECM proteins like the ED-A splice variant of fi bronectin, and 3) high extracellular stress, arising from the mechanical properties of the ECM and cell remodeling activity [8] . Differentiation of fi broblasts into MFs can be understood as a two-step process: 1) to re-populate damaged tissues, fi broblasts acquire a migratory phenotype by de novo developing contractile bundles. These in vivo stress fi bers are fi rst composed of cytoplasmic actins and generate comparably small traction forces. Most authors use the term "proto-myofi broblast" to discriminate such activated fi broblasts from quiescent fi broblasts that are devoid of any contractile apparatus in most intact tissues. This fi rst phenotypic change occurs in response to changes in the composition, organization, and mechanical property of ECM and to cytokines locally released by infl ammatory and resident cells [48] . 2) With increasing stress in the ECM resulting from their own remodeling activity, proto-myofi broblasts further develop into "differentiated myofi broblasts" by neo-expressing α-SMA, the most widely used myofi broblast marker [47, 49, 50] . Expression of α-SMA is precisely controlled by the joint action of growth factors like TGF-β1, of specialized ECM proteins like fi bronectin, splice variant ED-A fi bronectin, as well as the mechanical microenvironment. Incorporation of α-SMA into stress fi bers signifi cantly augments the contractile activity of fi broblastic cells and hallmarks the contraction phase of connective tissue remodeling [8, 51] .
IMMUNOHISTOCHEMICAL CHARACTERISTIC OF DORMANT AND ACTIVATED MFS
Quiescent HSCs express markers that are characteristic of adipocytes (PPARγ, SREBP-1c, and leptin), while activated HSCs express myogenic markers (α smooth muscle actin, c-myb, and myocyte enhancer factor-2).
The most widely used and accessible marker of these cells is the de novo expression of α-SMA, although this is not an absolute requirement for the identifi cation of a cell as a MF. Other markers of MFs (endosialin, P311, integrin α11β1, osteopontin, periostin) have been proposed, but all were identifi ed in specifi c conditions, and it remains unclear whether they could serve as general markers [49] .
About the immunophenotypic characteristics of dormant and activated MFs there is no unique data. The investigation of cytoskeletal and cell surface markers showed a certain degree of heterogeneity of these cells. The reason for this is that markers that these cells express on a large extent depend on the type of animal, age and stage of development of fi brosis [52] . There is information that the environment in which HSCs are located can determine their phenotype [53] .
The degree of activation of MFs and the development of fi brosis depend on the age of the animals. Young rats with a ligated bile duct rapidly increased the number of activated MFs and portal fi brosis developed faster than in adult rats [54] . The intensity of desmin expression in MFs after ligation is higher in young rats than in adults. In contrast to desmin, α-SMA expression between the two groups showed no statistical signifi cance [52] .
Investigation of HSCs in fi sh revealed the presence of beta-tubulin, α-SMA, smooth muscle type myosin, desmin and cytokeratin but not vimentin or glial fi brillar acidic protein [55] . Inactive HSCs in broilers express vimentin, desmin, GFAP and cytokeratine [56] .
In normal rat liver HSCs are situated in the perisinusoidal spaces and they are immunopositive to GFAP, desmin, vimentin, sinemin and V-CAM-1. Desmin and vimentin positive MFs in the rat liver have long cytoplasmatic extensions. Desmin expressing cells are visible in the portal spaces in arterial and venous blood vessels wall (portal fi broblasts). In normal liver parenchyma of rats α-SMA, β-tubulin, fi bulin-2, N-CAM and cytokeratine expression has not been proven [57, 58] . Activation of quiet HSCs and their consequent differentiation in MFs in humans and rats accompanied by expression of α-SMA, an isoform of actin, which is only present in smooth-muscle cells of blood vessels in normal or damaged liver [59] .
Contrary to rat liver, in normal canine livers perisinusoidal HSCs react positively to the α-SMA antibody (Fig. 1a) and are poorly positive to desmin (Fig. 1b) , diffusely, through the entire liver parenchyma. In the cytoplasm of these cells large lipid vacuoles with a dislocated nucleus to the periphery are revealed. The positive α-SMA reaction of smooth muscle cells of terminal and sublobular venous blood vessels are observed. In the portal triads, a positive reaction is observed in the arterial tunica media, and a slight positivity is observed in the walls of the portal veins. In normal canine liver HSCs are negative for vimentin and weakly positive for desmin, while the portal fi broblasts stain positive for vimentin and weakly positive for desmin [14, 60] .
In feline normal liver HSCs show a positive reaction with antibodies against α-SMA (Fig. 1c) and desmin (Fig. 1d) . Moderately discontinuous reactivity to α-SMA is present in the spaces of Disse, randomly distributed around the bile ducts and blood vessels and under the Glisson's capsule. Mild positive reaction to desmin is observed in portal blood vessels and some perisinusoidal cells [61] .
HSCs in normal porcine liver have long cytoplasmatic extensions, but they are shorter then cytoplasmatic extensions in rat HSCs. HSCs are desmin, vimentin and sinemin positive, but α-SMA negative in the liver of healthy swine. The number and size of the cytoplasmic vacuoles of porcine HSCs are constant irrespective of age and hepatic lipid contents [58, 62] .
In normal bovine liver HSCs are situated in the perisinusoidal spaces and have long cytoplasmatic extensions. In the citoplasm small vacuoles about 5 to 7μm in diameter are visible. Bovine HSCs are positive for desmin, but negative for α-SMA antibodies [62] .
In some wild animals, like fallow deer, hepatic MFs are similar to those described in domestic ruminants and in healthy animals are α-SMA (Fig. 1e) and desmin ( Fig. 1f) positive [63] .
In the early stage of fi brosis in the liver of rats a small amount of connective tissue and thin connective-tissue septa are present. The presence of cells that are positive for α-SMA, desmin and N-CAM can be seen in the connective-tissue septa (portal and/or septal MFs). Cells that are positive for desmin and GFAP are present at the interface between septa and hepatic parenchyma (interface MFs), as well as in the parenchyma (HSCs) [57] . In advanced stages of rat liver fi brosis mainly activated HSCs are immunoreactive for GFAP and desmin. HSCs in fi brotic rat liver show weak immunopositivity to α-SMA, N-CAM, synaptophysin, neurotrophins, neurotrophin receptors and alpha B-crystallin. Interface MFs at the septal/parenchymal interface showed an expression profi le, intermediate between the profi les of HSCs and portal/ septal MFs. They are immunoreactive to desmin, GFAP, α-SMA, N-CAM and alfa B-crystallin. If centrolobular fi brosis in rats is induced by bile duct ligation, the reaction of the second layer of cells around the central vein is observed. These cells express α-SMA, GFAP and alfa B-crystallin, a slightly weaker dezmin and N-CAM [13, 64] .
In canine liver with fi brosis, immunopositivity to α-SMA (Fig. 2a) , desmin (Fig. 2b) , and weakly to vimentin is observed on perisinusoidal HSCs and their long extensions, in the form of deposits are of a beaded appearance. Livers of dogs with moderate or severe fi brosis showed numerous α-SMA, desmin and vimentin positive cells in fi brous septs and the stroma that surrounded the regenerative lobules (portal/septal MFs). With the increase in the degree of fi brosis, the degree of expression of α-SMA also increased, both in the HSCs and in other localities [60, 65, 66] .
In the mildest forms of feline liver fi brosis α-SMA (Fig. 2c) and desmin ( Fig. 2d) is expressed in HSCs and portal/septal MFs. In the liver with moderate to severe fi brosis numerous α-SMA positive cells, presumable MFs, are present in the fi brous septa, and stroma surrounding regenerative nodules. In feline liver with periportal and septal fi brosis α-SMA is detected in round and spindle-shaped cells around bile ducts and blood vessel walls. Scarce interface stellate cells and perisinusoidal cells with processes showed an intensive positive reaction to α-SMA. In fi brous septa a positive reaction to desmin was detected in MFs and blood vessels, as well as in some HSCs at the periphery of the lobuli [61] .
MFs in bovine liver due to Fasciola infection are spindle-shaped and positive for vimentin, desmin and α-SMA. These cells are increased in the peribiliary connective tissue, although the desmin-positive cells are fewer [67] . Similarly to those, HSCs, portal/septal MFs and interface MFs are positive to α-SMA (Fig. 2e) and desmin ( Fig.  2f ) in the liver of fallow deer due to Fascioloides magna infection [63] . 
